# A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

> **NCT03410979** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 79 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG2737 single dose
- **DRUG:** Placebo single dose
- **DRUG:** GLPG2737 multiple dose
- **DRUG:** GLPG2737 multiple dose

## Key facts

- **NCT ID:** NCT03410979
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-25
- **Primary completion:** 2017-08-15
- **Final completion:** 2017-08-15
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2018-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03410979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03410979, "A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03410979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*